Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
The pharmacodynamic properties of low-molecular-weight heparins differ. Data from randomized clinical trials show that despite these differences, the agents have similar efficacy and safety profiles in preventing and treating new and recurrent venous thromboembolism in patients who underwent general surgery or total hip or knee replacement. Dalteparin, enoxaparin, or tinzaparin, when administered at the dosages used in the reviewed clinical trials, are essentially indistinguishable.
Lopez
L M
LM
College of Pharmacy, University of Florida, Gainesville 32610-0486, USA.
D002986:Clinical Trials as Topic; D017985:Dalteparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000517:prevention & control; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control*
D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin; D017985:Dalteparin